- Home
- NERV vs NRXS Comparison
NERV vs NRXS Comparison
Compare NERV & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NRXS
- Stock Information
- Founded
- NERV 2007
- NRXS 2011
- Country
- NERV United States
- NRXS United States
- Employees
- NERV N/A
- NRXS N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- NERV Health Care
- NRXS
- Exchange
- NERV Nasdaq
- NRXS Nasdaq
- Market Cap
- NERV 12.0M
- NRXS 13.0M
- IPO Year
- NERV 2014
- NRXS 2023
- Fundamental
- Price
- NERV $2.25
- NRXS $2.41
- Analyst Decision
- NERV Hold
- NRXS Strong Buy
- Analyst Count
- NERV 1
- NRXS 1
- Target Price
- NERV $5.00
- NRXS $7.00
- AVG Volume (30 Days)
- NERV 35.1K
- NRXS 55.7K
- Earning Date
- NERV 08-14-2025
- NRXS 08-12-2025
- Dividend Yield
- NERV N/A
- NRXS N/A
- EPS Growth
- NERV N/A
- NRXS N/A
- EPS
- NERV 1.48
- NRXS N/A
- Revenue
- NERV N/A
- NRXS $3,217,531.00
- Revenue This Year
- NERV N/A
- NRXS $73.05
- Revenue Next Year
- NERV N/A
- NRXS $130.42
- P/E Ratio
- NERV $1.52
- NRXS N/A
- Revenue Growth
- NERV N/A
- NRXS 41.93
- 52 Week Low
- NERV $1.15
- NRXS $1.33
- 52 Week High
- NERV $3.00
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- NERV 69.92
- NRXS 42.66
- Support Level
- NERV $1.79
- NRXS $2.26
- Resistance Level
- NERV $1.81
- NRXS $2.57
- Average True Range (ATR)
- NERV 0.10
- NRXS 0.14
- MACD
- NERV 0.01
- NRXS -0.02
- Stochastic Oscillator
- NERV 76.56
- NRXS 37.94
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).